Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $657000.0.

  • Cytek Biosciences' Capital Expenditures fell 3501.48% to $657000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year decrease of 372.79%. This contributed to the annual value of $3.5 million for FY2024, which is 2416.09% down from last year.
  • Cytek Biosciences' Capital Expenditures amounted to $657000.0 in Q3 2025, which was down 3501.48% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Cytek Biosciences' Capital Expenditures peaked at $6.5 million during Q4 2022, and registered a low of $505000.0 during Q1 2023.
  • In the last 5 years, Cytek Biosciences' Capital Expenditures had a median value of $1.1 million in 2022 and averaged $1.3 million.
  • Per our database at Business Quant, Cytek Biosciences' Capital Expenditures surged by 53842.36% in 2021 and then plummeted by 7702.91% in 2023.
  • Over the past 5 years, Cytek Biosciences' Capital Expenditures (Quarter) stood at $1.3 million in 2021, then soared by 403.86% to $6.5 million in 2022, then plummeted by 77.03% to $1.5 million in 2023, then crashed by 40.4% to $894000.0 in 2024, then decreased by 26.51% to $657000.0 in 2025.
  • Its last three reported values are $657000.0 in Q3 2025, $1.6 million for Q2 2025, and $849000.0 during Q1 2025.